董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David P. Bonita | 男 | Director | 43 | 未披露 | 未持股 | 2018-09-30 |
| Jeffrey W. Dunn | 男 | President, Chief Executive Officer and Chairman | 64 | 117.88万美元 | 未持股 | 2018-09-30 |
| Karen A. Licitra | 女 | Director | 59 | 未披露 | 未持股 | 2018-09-30 |
| Timothy B. Petersen | 男 | Director | 54 | 未披露 | 未持股 | 2018-09-30 |
| Mark A. Reiley | 男 | Director | 68 | 未披露 | 未持股 | 2018-09-30 |
| Karen A. Licitra | 女 | Director | 59 | 2.40万美元 | 未持股 | 2018-09-30 |
| Gregory K. Hinckley | 男 | Director | 71 | 2.40万美元 | 未持股 | 2018-09-30 |
| Keith C. Valentine | 男 | Director | 51 | 2.40万美元 | 未持股 | 2018-09-30 |
| John G. Freund | 男 | Director | 64 | 未披露 | 未持股 | 2018-09-30 |
| Timothy E. Davis, Jr. | 男 | Director | 48 | 2.40万美元 | 未持股 | 2018-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey W. Dunn | 男 | President, Chief Executive Officer and Chairman | 64 | 117.88万美元 | 未持股 | 2018-09-30 |
| Laura A. Francis | 女 | Chief Financial Officer | 51 | 51.85万美元 | 未持股 | 2018-09-30 |
| Michael A. Pisetsky | 男 | General Counsel and Chief Compliance Officer | 40 | 未披露 | 未持股 | 2018-09-30 |
| W. Carlton Reckling | 男 | Chief Medical Officer and Vice President, Medical Affairs | 56 | 未披露 | 未持股 | 2018-09-30 |
| Anthony J. Recupero | 男 | Chief Commercial Officer | 60 | 58.39万美元 | 未持股 | 2018-09-30 |
| Scott A. Yerby | 男 | Chief Technology Officer | 50 | 未披露 | 未持股 | 2018-09-30 |
董事简历
中英对照 | 中文 | 英文- David P. Bonita
-
DavidP.Bonita自2014年4月以来一直担任我们的董事会成员。自2013年6月以来，Bonita博士还担任OrbiMed Advisors LLC（一家专注于梦百合行业的投资公司）的私募股权合伙人。Bonita从2004年6月到2013年6月在OrbiMed担任多个职位。在加入OrbiMed之前，Bonita博士从1998年2月到1999年7月是摩根士丹利梦百合投资银行集团的公司财务分析师。Bonita从1997年8月到1998年2月担任UBS AG（一家全球金融服务公司）梦百合Investment Banking Group企业金融分析师。Bonita博士曾担任并继续担任多家私营和上市公司的董事，其中包括2013年6月至今的专注于骨病和其他疾病的药物开发商Clementia Pharmaceuticals，Inc.，以及专注于肾脏疾病的药物开发商Tricida，Inc.，2014年1月至今；2013年10月至2017年12月，肿瘤药物开发商LoxoOncology，Inc.；2008年1月至2018年6月，放射治疗和成像技术设计和制造商Viewray Inc.；以及专注于肿瘤和自身免疫的药物开发商Ambit Biosciences Corporation，和炎症性疾病从2012年10月到2014年11月。Bonita博士在哈佛大学（Harvard University）获得生物科学学士学位，并在哥伦比亚大学（Columbia University）获得联合医学博士/工商管理硕士学位。
David P. Bonita has served as a member of Third Harmonic Bio, Inc. board of directors since July 2020. Dr. Bonita is currently a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2004. Dr. Bonita currently serves on the boards of directors of Acutus Medical, Inc., Ikena Oncology, Inc., IMARA Inc., Prelude Therapeutics, Inc., Repare Therapeutics Inc., and Tricida, Inc., as well as several private companies. Dr. Bonita previously served on the boards of directors of several companies, including Clementia Pharmaceuticals Inc., Loxo Oncology, Inc., SI-BONE Inc., and ViewRay Inc. Dr. Bonita has also worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientific articles in peer-reviewed journals based on signal transduction research performed at the Harvard Medical School. He received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University. - DavidP.Bonita自2014年4月以来一直担任我们的董事会成员。自2013年6月以来，Bonita博士还担任OrbiMed Advisors LLC（一家专注于梦百合行业的投资公司）的私募股权合伙人。Bonita从2004年6月到2013年6月在OrbiMed担任多个职位。在加入OrbiMed之前，Bonita博士从1998年2月到1999年7月是摩根士丹利梦百合投资银行集团的公司财务分析师。Bonita从1997年8月到1998年2月担任UBS AG（一家全球金融服务公司）梦百合Investment Banking Group企业金融分析师。Bonita博士曾担任并继续担任多家私营和上市公司的董事，其中包括2013年6月至今的专注于骨病和其他疾病的药物开发商Clementia Pharmaceuticals，Inc.，以及专注于肾脏疾病的药物开发商Tricida，Inc.，2014年1月至今；2013年10月至2017年12月，肿瘤药物开发商LoxoOncology，Inc.；2008年1月至2018年6月，放射治疗和成像技术设计和制造商Viewray Inc.；以及专注于肿瘤和自身免疫的药物开发商Ambit Biosciences Corporation，和炎症性疾病从2012年10月到2014年11月。Bonita博士在哈佛大学（Harvard University）获得生物科学学士学位，并在哥伦比亚大学（Columbia University）获得联合医学博士/工商管理硕士学位。
- David P. Bonita has served as a member of Third Harmonic Bio, Inc. board of directors since July 2020. Dr. Bonita is currently a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2004. Dr. Bonita currently serves on the boards of directors of Acutus Medical, Inc., Ikena Oncology, Inc., IMARA Inc., Prelude Therapeutics, Inc., Repare Therapeutics Inc., and Tricida, Inc., as well as several private companies. Dr. Bonita previously served on the boards of directors of several companies, including Clementia Pharmaceuticals Inc., Loxo Oncology, Inc., SI-BONE Inc., and ViewRay Inc. Dr. Bonita has also worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientific articles in peer-reviewed journals based on signal transduction research performed at the Harvard Medical School. He received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University.
- Jeffrey W. Dunn
-
自2008年4月成立以来，JeffreyW.Dunn一直担任我们的总裁兼首席执行官，并担任董事会主席。加入我们之前，Dunn从2006年12月到2008年4月担任Inbone Technologies，Inc.（一家踝关节置换和小骨融合医疗设备公司）首席执行官，直到2008年4月出售给Wright Medical Technology，Inc.。Dunn从2000年8月到2006年6月担任Active Decisions，Inc.（一家软件即服务业务）首席执行官，直到该公司出售给Knova Software，Inc.。Dunn从1999年12月到2000年6月担任Velogic，Inc.（一家互联网性能测试软件公司）首席执行官，直到该公司出售给Keynote Systems Inc.。Dunn从1999年6月到1999年12月担任EnterpriseLink Inc.（企业互联网使能软件供应商）首席执行官，直到该公司出售给Merant，Inc.。Dunn从1994年11月到1998年6月担任AccelGraphics Inc.（一家3D图形系统供应商）首席执行官，直到该公司出售给Evans and Sutherland Computer Corporation。在他的职业生涯中，邓恩先生还在埃文斯公司、萨瑟兰公司、Cygnet Systems公司、Avnet，Inc.公司和施乐公司担任过行政职务。Dunn先生在高露洁大学（Colgate University）获得文学学士学位，在巴布森学院（Babson College）获得工商管理硕士学位。
Jeffrey W. Dunn has served as our President and Chief Executive Officer and as the Chairman of our board of directors since our inception in April 2008. Prior to joining us, Mr. Dunn served as Chief Executive Officer of INBONE Technologies, Inc., an ankle replacement and small bone fusion medical device company, from December 2006 to April 2008 until its sale to Wright Medical Technology, Inc. in April 2008. From August 2000 to June 2006 Mr. Dunn was the Chief Executive Officer of Active Decisions, Inc., a software as a service business, until its sale to Knova Software, Inc. From December 1999 to June 2000 Mr. Dunn was the Chief Executive Officer of Velogic, Inc., an internet performance testing software company, until its sale to Keynote Systems Inc. From June 1999 to December 1999 Mr. Dunn was the Chief Executive Officer of EnterpriseLink Inc., a provider of enterprise Internet enablement software, until its sale to Merant, Inc. From November 1994 to June 1998 Mr. Dunn was Chief Executive Officer of AccelGraphics Inc., a 3D graphics system supplier, until its sale to Evans and Sutherland Computer Corporation. As well, during his career, Mr. Dunn held executive positions with Evans and Sutherland, Cygnet Systems, Inc., Avnet, Inc. and Xerox Corporation. Mr. Dunn received a B.A. from Colgate University and an M.B.A. from Babson College. - 自2008年4月成立以来，JeffreyW.Dunn一直担任我们的总裁兼首席执行官，并担任董事会主席。加入我们之前，Dunn从2006年12月到2008年4月担任Inbone Technologies，Inc.（一家踝关节置换和小骨融合医疗设备公司）首席执行官，直到2008年4月出售给Wright Medical Technology，Inc.。Dunn从2000年8月到2006年6月担任Active Decisions，Inc.（一家软件即服务业务）首席执行官，直到该公司出售给Knova Software，Inc.。Dunn从1999年12月到2000年6月担任Velogic，Inc.（一家互联网性能测试软件公司）首席执行官，直到该公司出售给Keynote Systems Inc.。Dunn从1999年6月到1999年12月担任EnterpriseLink Inc.（企业互联网使能软件供应商）首席执行官，直到该公司出售给Merant，Inc.。Dunn从1994年11月到1998年6月担任AccelGraphics Inc.（一家3D图形系统供应商）首席执行官，直到该公司出售给Evans and Sutherland Computer Corporation。在他的职业生涯中，邓恩先生还在埃文斯公司、萨瑟兰公司、Cygnet Systems公司、Avnet，Inc.公司和施乐公司担任过行政职务。Dunn先生在高露洁大学（Colgate University）获得文学学士学位，在巴布森学院（Babson College）获得工商管理硕士学位。
- Jeffrey W. Dunn has served as our President and Chief Executive Officer and as the Chairman of our board of directors since our inception in April 2008. Prior to joining us, Mr. Dunn served as Chief Executive Officer of INBONE Technologies, Inc., an ankle replacement and small bone fusion medical device company, from December 2006 to April 2008 until its sale to Wright Medical Technology, Inc. in April 2008. From August 2000 to June 2006 Mr. Dunn was the Chief Executive Officer of Active Decisions, Inc., a software as a service business, until its sale to Knova Software, Inc. From December 1999 to June 2000 Mr. Dunn was the Chief Executive Officer of Velogic, Inc., an internet performance testing software company, until its sale to Keynote Systems Inc. From June 1999 to December 1999 Mr. Dunn was the Chief Executive Officer of EnterpriseLink Inc., a provider of enterprise Internet enablement software, until its sale to Merant, Inc. From November 1994 to June 1998 Mr. Dunn was Chief Executive Officer of AccelGraphics Inc., a 3D graphics system supplier, until its sale to Evans and Sutherland Computer Corporation. As well, during his career, Mr. Dunn held executive positions with Evans and Sutherland, Cygnet Systems, Inc., Avnet, Inc. and Xerox Corporation. Mr. Dunn received a B.A. from Colgate University and an M.B.A. from Babson College.
- Karen A. Licitra
-
KarenA.Licitra自2015年8月以来一直担任我们的董事会成员。2014年1月至2015年8月，Licitra女士在医疗器械、制药和消费品制造商强生公司担任企业Vice President，负责全球政府事务和政策。从2011年12月到2013年12月，Licitra女士担任强生公司全球医疗解决方案的全球主席。从2002年7月到2011年11月，她曾担任Ethicon Endo-Surgery公司（强生公司医疗设备公司）的公司集团主席兼全球特许经营主席。2001年1月至2002年6月，她担任Ethicon Endo-Surgery的总裁。Licitra女士目前在Novadaq TechnologiesInc.公司董事会任职，该公司是一家经过验证的全面荧光成像解决方案提供商。Licitra女士在莱德学院（Rider College）获得商学学士学位。
Karen A. Licitra has served as a member of our board of directors since August 2015. From January 2014 through August 2015 Ms. Licitra served as Corporate Vice President, Worldwide Government Affairs & Policy at Johnson & Johnson, a medical devices, pharmaceutical, and consumer packaged goods manufacturer. From December 2011 to December 2013 Ms. Licitra served as the Worldwide Chairman, Global Medical Solutions at Johnson & Johnson. From July 2002 to November 2011 she served as the Company Group Chairman and Worldwide Franchise Chairman at Ethicon Endo-Surgery, Inc., a Johnson & Johnson medical device company. From January 2001 to June 2002 she served as the President of Ethicon Endo-Surgery. Ms. Licitra currently serves on the board of directors of Novadaq Technologies Inc., a provider of proven comprehensive fluorescence imaging solutions. Ms. Licitra received a B.S. in Commerce from Rider College. - KarenA.Licitra自2015年8月以来一直担任我们的董事会成员。2014年1月至2015年8月，Licitra女士在医疗器械、制药和消费品制造商强生公司担任企业Vice President，负责全球政府事务和政策。从2011年12月到2013年12月，Licitra女士担任强生公司全球医疗解决方案的全球主席。从2002年7月到2011年11月，她曾担任Ethicon Endo-Surgery公司（强生公司医疗设备公司）的公司集团主席兼全球特许经营主席。2001年1月至2002年6月，她担任Ethicon Endo-Surgery的总裁。Licitra女士目前在Novadaq TechnologiesInc.公司董事会任职，该公司是一家经过验证的全面荧光成像解决方案提供商。Licitra女士在莱德学院（Rider College）获得商学学士学位。
- Karen A. Licitra has served as a member of our board of directors since August 2015. From January 2014 through August 2015 Ms. Licitra served as Corporate Vice President, Worldwide Government Affairs & Policy at Johnson & Johnson, a medical devices, pharmaceutical, and consumer packaged goods manufacturer. From December 2011 to December 2013 Ms. Licitra served as the Worldwide Chairman, Global Medical Solutions at Johnson & Johnson. From July 2002 to November 2011 she served as the Company Group Chairman and Worldwide Franchise Chairman at Ethicon Endo-Surgery, Inc., a Johnson & Johnson medical device company. From January 2001 to June 2002 she served as the President of Ethicon Endo-Surgery. Ms. Licitra currently serves on the board of directors of Novadaq Technologies Inc., a provider of proven comprehensive fluorescence imaging solutions. Ms. Licitra received a B.S. in Commerce from Rider College.
- Timothy B. Petersen
-
TimothyB.Petersen自2016年6月以来一直担任我们的董事会成员。Petersen先生从2002年4月开始受雇于Arboretum Ventures，Inc.。作为公司的董事总经理，他的投资主要针对资本效率高的医疗设备、健康IT和服务公司。Petersen先生曾在超过15家公司领导投资并担任Arboretum的董事，其中包括被强生公司收购的HealthMedia、Accuri Cytometers Inc.（被Becton Dickinson收购）、Intellicht Corporation（被Sartorius AG收购）和Inogen。Petersen先生目前在我们公司之外的几家私人公司的董事会任职。Petersen先生拥有威廉姆斯学院（Williams College）经济学学士学位，威斯康星大学麦迪逊分校（University of Wisconsin-Madison）经济学硕士学位和密歇根大学罗斯商学院（Ross School of Business at the University of Michigan）工商管理硕士学位。
Timothy B. Petersen has served as a member of our board of directors since June 2016. Since April 2002 Mr. Petersen has been employed by Arboretum Ventures, Inc. As a Managing Director of the firm, his investments primarily target capital-efficient medical device, health IT and services companies. Mr. Petersen has led investments and held board seats for Arboretum in more than fifteen companies, including HealthMedia acquired by Johnson & Johnson, Accuri Cytometers Inc. (acquired by Becton Dickinson), IntelliCyt Corporation (acquired by Sartorius AG) and Inogen. Mr. Petersen currently serves on the boards of several private companies in addition to our Company. Mr. Petersen holds a B.A. in Economics from Williams College, an M.S. in Economics from the University of Wisconsin-Madison, and an M.B.A. from the Ross School of Business at the University of Michigan. - TimothyB.Petersen自2016年6月以来一直担任我们的董事会成员。Petersen先生从2002年4月开始受雇于Arboretum Ventures，Inc.。作为公司的董事总经理，他的投资主要针对资本效率高的医疗设备、健康IT和服务公司。Petersen先生曾在超过15家公司领导投资并担任Arboretum的董事，其中包括被强生公司收购的HealthMedia、Accuri Cytometers Inc.（被Becton Dickinson收购）、Intellicht Corporation（被Sartorius AG收购）和Inogen。Petersen先生目前在我们公司之外的几家私人公司的董事会任职。Petersen先生拥有威廉姆斯学院（Williams College）经济学学士学位，威斯康星大学麦迪逊分校（University of Wisconsin-Madison）经济学硕士学位和密歇根大学罗斯商学院（Ross School of Business at the University of Michigan）工商管理硕士学位。
- Timothy B. Petersen has served as a member of our board of directors since June 2016. Since April 2002 Mr. Petersen has been employed by Arboretum Ventures, Inc. As a Managing Director of the firm, his investments primarily target capital-efficient medical device, health IT and services companies. Mr. Petersen has led investments and held board seats for Arboretum in more than fifteen companies, including HealthMedia acquired by Johnson & Johnson, Accuri Cytometers Inc. (acquired by Becton Dickinson), IntelliCyt Corporation (acquired by Sartorius AG) and Inogen. Mr. Petersen currently serves on the boards of several private companies in addition to our Company. Mr. Petersen holds a B.A. in Economics from Williams College, an M.S. in Economics from the University of Wisconsin-Madison, and an M.B.A. from the Ross School of Business at the University of Michigan.
- Mark A. Reiley
-
MarkA.Reiley自2008年4月成立以来一直担任我们的董事会成员，并从成立至2016年9月担任我们的首席医疗官。Reiley博士还从2014年4月开始担任Reiley Pharmaceuticals，Inc.的首席医疗官，这是一家制药公司。此前，Reiley从2009年3月到2010年10月担任Fixes-4-Kids，Inc.首席医疗官。在加入我们之前，Reiley博士从2004年12月到2008年4月是Inbone Technologies的首席医疗官，直到2008年4月它被出售给Wright Medical Technology，Inc.。Reiley从1990年10月到2007年5月担任Kyphon Inc.（一家医疗设备公司，专注于脊柱椎体压缩性骨折的治疗）首席医疗官，直到该公司出售给美敦力公司（现为Medtronic plc）。在此期间，从2001年10月到2005年3月，Reiley博士担任Archus Orthopedics Inc.的首席医疗官，该公司是一家全方面替代医疗设备公司。Reiley博士还是Berkeley Orthopedics Surgical Group的创始成员，在那里他练习了超过25年，并在加州大学伯克利分校（University of California at Berkeley）培训学生和教员。他曾创立并任职于各种私人公司的董事会。Reiley博士在克莱蒙特男子学院（Claremont Men&8217；s College）获得学士学位，并在乔治华盛顿大学医学院（George Washington University School of Medicine）获得医学博士学位，他在加州大学旧金山分校（University of California at San Francisco）完成骨科住院医师和研究金。
Mark A. Reiley has served as a member of our board of directors since our inception in April 2008 and as our Chief Medical Officer from inception to September 2016. Dr. Reiley has also served as Chief Medical Officer of Reiley Pharmaceuticals, Inc., a pharmaceutical company, since April 2014. Previously, Dr. Reiley was Chief Medical officer of Fixes-4-Kids, Inc. from March 2009 to October 2010. Prior to joining us, Dr. Reiley was the Chief Medical Officer of INBONE Technologies from December 2004 to April 2008 until its sale to Wright Medical Technology, Inc. in April 2008. From October 1990 to May 2007 Dr. Reiley was Chief Medical Officer of Kyphon Inc., a medical device company focused on the treatment of vertebral compression fractures of the spine, until its sale to Medtronic, Inc. now Medtronic plc. During that period, from October 2001 to March 2005 Dr. Reiley was Chief Medical officer of Archus Orthopedics Inc., a total facet replacement medical device company. Dr. Reiley was also a founding member of Berkeley Orthopedics Surgical group, where he practiced for over 25 years and trained the students and faculty at the University of California at Berkeley. He has founded and served on the boards of various private companies. Dr. Reiley received a B.A. from Claremont Men’s College and an M.D. from George Washington University School of Medicine, and he completed both his orthopedic residency and fellowship at the University of California at San Francisco. - MarkA.Reiley自2008年4月成立以来一直担任我们的董事会成员，并从成立至2016年9月担任我们的首席医疗官。Reiley博士还从2014年4月开始担任Reiley Pharmaceuticals，Inc.的首席医疗官，这是一家制药公司。此前，Reiley从2009年3月到2010年10月担任Fixes-4-Kids，Inc.首席医疗官。在加入我们之前，Reiley博士从2004年12月到2008年4月是Inbone Technologies的首席医疗官，直到2008年4月它被出售给Wright Medical Technology，Inc.。Reiley从1990年10月到2007年5月担任Kyphon Inc.（一家医疗设备公司，专注于脊柱椎体压缩性骨折的治疗）首席医疗官，直到该公司出售给美敦力公司（现为Medtronic plc）。在此期间，从2001年10月到2005年3月，Reiley博士担任Archus Orthopedics Inc.的首席医疗官，该公司是一家全方面替代医疗设备公司。Reiley博士还是Berkeley Orthopedics Surgical Group的创始成员，在那里他练习了超过25年，并在加州大学伯克利分校（University of California at Berkeley）培训学生和教员。他曾创立并任职于各种私人公司的董事会。Reiley博士在克莱蒙特男子学院（Claremont Men&8217；s College）获得学士学位，并在乔治华盛顿大学医学院（George Washington University School of Medicine）获得医学博士学位，他在加州大学旧金山分校（University of California at San Francisco）完成骨科住院医师和研究金。
- Mark A. Reiley has served as a member of our board of directors since our inception in April 2008 and as our Chief Medical Officer from inception to September 2016. Dr. Reiley has also served as Chief Medical Officer of Reiley Pharmaceuticals, Inc., a pharmaceutical company, since April 2014. Previously, Dr. Reiley was Chief Medical officer of Fixes-4-Kids, Inc. from March 2009 to October 2010. Prior to joining us, Dr. Reiley was the Chief Medical Officer of INBONE Technologies from December 2004 to April 2008 until its sale to Wright Medical Technology, Inc. in April 2008. From October 1990 to May 2007 Dr. Reiley was Chief Medical Officer of Kyphon Inc., a medical device company focused on the treatment of vertebral compression fractures of the spine, until its sale to Medtronic, Inc. now Medtronic plc. During that period, from October 2001 to March 2005 Dr. Reiley was Chief Medical officer of Archus Orthopedics Inc., a total facet replacement medical device company. Dr. Reiley was also a founding member of Berkeley Orthopedics Surgical group, where he practiced for over 25 years and trained the students and faculty at the University of California at Berkeley. He has founded and served on the boards of various private companies. Dr. Reiley received a B.A. from Claremont Men’s College and an M.D. from George Washington University School of Medicine, and he completed both his orthopedic residency and fellowship at the University of California at San Francisco.
- Karen A. Licitra
-
Karen A. Licitra于2019年7月17日获委任填补Angiodynamics, Inc.董事会职位空缺。自2014年1月至2015年8月，Licitra女士担任强生公司全球政府事务及政策公司副总裁，医疗器械，制药和包装消费品制造商。 2011年12月至2013年12月，Licitra女士担任强生公司全球医疗解决方案全球主席。从2002年7月至2011年11月，她在强生医疗器械公司Ethicon Endo-Surgery，Inc.担任公司集团主席和全球特许经营主席。从2001年1月到2002年6月，她担任Ethicon Endo-Surgery的总裁。 Licitra女士目前是Si-Bone，Inc.的医疗器械公司的董事会成员，该公司专注于治疗骶髂关节功能障碍的微创手术植入系统，此前曾在Novadaq Technologies Inc.的董事会任职。提供经过验证的全面荧光成像解决方案，直到该公司于2017年被Stryker公司收购。Licitra女士获得了学士学位来自Rider College的商业。
Karen A. Licitra,Ms. Licitra joined Angiodynamics, Inc. Board of Directors in July of 2019. From January 2014 through August 2015, Ms. Licitra served as Corporate Vice President, Worldwide Government Affairs & Policy at Johnson & Johnson, a medical devices, pharmaceutical, and consumer packaged goods manufacturer. From December 2011 to December 2013, Ms. Licitra served as the Worldwide Chairman, Global Medical Solutions at Johnson & Johnson. From July 2002 to November 2011, she served as the Company Group Chairman and Worldwide Franchise Chairman at Ethicon Endo-Surgery, Inc., a Johnson & Johnson medical device company. From January 2001 to June 2002, she served as the President of Ethicon Endo-Surgery. From June 2015 to June 2021, she served on the Compensation Committee of the Board of Directors of Si-Bone, Inc., a medical device company focusing on a minimally invasive surgical implant system to treat sacroiliac joint dysfunction, and previously served on the Board of Directors of Novadaq Technologies Inc., a provider of proven comprehensive fluorescence imaging solutions, until the company was acquired by Stryker Corporation in 2017. Ms. Licitra received a B.S. in Commerce from Rider College. Ms. Licitra is a member of Angiodynamics, Inc. Audit Committee and Angiodynamics, Inc. Compensation Committee. - Karen A. Licitra于2019年7月17日获委任填补Angiodynamics, Inc.董事会职位空缺。自2014年1月至2015年8月，Licitra女士担任强生公司全球政府事务及政策公司副总裁，医疗器械，制药和包装消费品制造商。 2011年12月至2013年12月，Licitra女士担任强生公司全球医疗解决方案全球主席。从2002年7月至2011年11月，她在强生医疗器械公司Ethicon Endo-Surgery，Inc.担任公司集团主席和全球特许经营主席。从2001年1月到2002年6月，她担任Ethicon Endo-Surgery的总裁。 Licitra女士目前是Si-Bone，Inc.的医疗器械公司的董事会成员，该公司专注于治疗骶髂关节功能障碍的微创手术植入系统，此前曾在Novadaq Technologies Inc.的董事会任职。提供经过验证的全面荧光成像解决方案，直到该公司于2017年被Stryker公司收购。Licitra女士获得了学士学位来自Rider College的商业。
- Karen A. Licitra,Ms. Licitra joined Angiodynamics, Inc. Board of Directors in July of 2019. From January 2014 through August 2015, Ms. Licitra served as Corporate Vice President, Worldwide Government Affairs & Policy at Johnson & Johnson, a medical devices, pharmaceutical, and consumer packaged goods manufacturer. From December 2011 to December 2013, Ms. Licitra served as the Worldwide Chairman, Global Medical Solutions at Johnson & Johnson. From July 2002 to November 2011, she served as the Company Group Chairman and Worldwide Franchise Chairman at Ethicon Endo-Surgery, Inc., a Johnson & Johnson medical device company. From January 2001 to June 2002, she served as the President of Ethicon Endo-Surgery. From June 2015 to June 2021, she served on the Compensation Committee of the Board of Directors of Si-Bone, Inc., a medical device company focusing on a minimally invasive surgical implant system to treat sacroiliac joint dysfunction, and previously served on the Board of Directors of Novadaq Technologies Inc., a provider of proven comprehensive fluorescence imaging solutions, until the company was acquired by Stryker Corporation in 2017. Ms. Licitra received a B.S. in Commerce from Rider College. Ms. Licitra is a member of Angiodynamics, Inc. Audit Committee and Angiodynamics, Inc. Compensation Committee.
- Gregory K. Hinckley
-
Gregory K. Hinckley在Mentor Graphics工作了20年后，于2017年7月从Mentor Graphics Corporation退休，Mentor Graphics Corporation是电子设计计算机自动化软件的领导者。1999年至2017年7月，他担任Mentor Graphics总裁。从1997年到1999年，他担任Mentor Graphics的执行副总裁、首席运营和财务官。在1997年加入Mentor Graphics之前，Hinckley先生曾在VLSI Technology，Inc.担任首席财务官，VLSI Technology，Inc.是一家上市的综合半导体器件公司，1992-1997年在Crowley Maritime Corporation任职，1989-1991年在Bio-Rad任职，1983-1989年在Bio-Rad Laboratories, Inc.任职。他目前担任SI-BONE, Inc.的董事和审计委员会成员，SI-BONE公司是一家上市的骨科器械公司。Hinckley先生还担任Claremont McKenna College和Portland State University的董事，并担任校董会主席。Hinckley先生曾担任其他几家上市公司的董事，包括自动识别和数据收集AIDC解决方案的上市供应商Intermec，Inc.，高级计算机服务器系统和子系统的上市供应商Super Micro，以及外包半导体互连服务的领先供应商Amkor Technology。Hinckley拥有40多年的上市公司经验。
Gregory K. Hinckley,retired from Mentor Graphics Corporation, a leader in computer automated software for electronics design, in July 2017 after 20 years at Mentor Graphics. From 1999 to July 2017, he served as President of Mentor Graphics. From 1997 to 1999, he served as Mentor Graphics' Executive Vice President, Chief Operating and Financial Officer. Prior to joining Mentor Graphics in 1997, Mr. Hinckley served as Chief Financial Officer for VLSI Technology, Inc., a publicly traded integrated semiconductor device company, from 1992-1997, for Crowley Maritime Corporation from 1989-1991 and for Bio-Rad from 1983-1989. He currently serves as a director and on the Audit Committee of SI-BONE, Inc., a publicly traded orthopedic device company, and on the Board of Portland State University. Mr. Hinckley previously served as a director for several other publicly traded companies including Intermec, Inc., a publicly traded provider of automated identification and data collection (AIDC) solutions, Super Micro, a publicly traded provider of advanced computer server systems and subsystems, and Amkor Technology, a leading supplier of outsourced semiconductor interconnect services. Mr. Hinckley has over 40 years of public company experience. - Gregory K. Hinckley在Mentor Graphics工作了20年后，于2017年7月从Mentor Graphics Corporation退休，Mentor Graphics Corporation是电子设计计算机自动化软件的领导者。1999年至2017年7月，他担任Mentor Graphics总裁。从1997年到1999年，他担任Mentor Graphics的执行副总裁、首席运营和财务官。在1997年加入Mentor Graphics之前，Hinckley先生曾在VLSI Technology，Inc.担任首席财务官，VLSI Technology，Inc.是一家上市的综合半导体器件公司，1992-1997年在Crowley Maritime Corporation任职，1989-1991年在Bio-Rad任职，1983-1989年在Bio-Rad Laboratories, Inc.任职。他目前担任SI-BONE, Inc.的董事和审计委员会成员，SI-BONE公司是一家上市的骨科器械公司。Hinckley先生还担任Claremont McKenna College和Portland State University的董事，并担任校董会主席。Hinckley先生曾担任其他几家上市公司的董事，包括自动识别和数据收集AIDC解决方案的上市供应商Intermec，Inc.，高级计算机服务器系统和子系统的上市供应商Super Micro，以及外包半导体互连服务的领先供应商Amkor Technology。Hinckley拥有40多年的上市公司经验。
- Gregory K. Hinckley,retired from Mentor Graphics Corporation, a leader in computer automated software for electronics design, in July 2017 after 20 years at Mentor Graphics. From 1999 to July 2017, he served as President of Mentor Graphics. From 1997 to 1999, he served as Mentor Graphics' Executive Vice President, Chief Operating and Financial Officer. Prior to joining Mentor Graphics in 1997, Mr. Hinckley served as Chief Financial Officer for VLSI Technology, Inc., a publicly traded integrated semiconductor device company, from 1992-1997, for Crowley Maritime Corporation from 1989-1991 and for Bio-Rad from 1983-1989. He currently serves as a director and on the Audit Committee of SI-BONE, Inc., a publicly traded orthopedic device company, and on the Board of Portland State University. Mr. Hinckley previously served as a director for several other publicly traded companies including Intermec, Inc., a publicly traded provider of automated identification and data collection (AIDC) solutions, Super Micro, a publicly traded provider of advanced computer server systems and subsystems, and Amkor Technology, a leading supplier of outsourced semiconductor interconnect services. Mr. Hinckley has over 40 years of public company experience.
- Keith C. Valentine
-
Keith C. Valentine从2007年一月份开始担任我们的主席和首席运营官。在2004年12月到2007年1月期间，他是我们的主席，在2002年1月到2004年12月期间，他是我们的执行副主席。在那之前，他是我们的营销发展高级副主席。他在整形行业有超过20年的经验，曾在ORATEC Interventions, Inc.担任营销副主席，这是一家医疗器械公司，后来被Smith & Nephew plc收购，在Medtronic Sofamor Danek工作的8年时间里，他辗转很多岗位，包括Rods Division市场营销副主席，BMP Biologics program, the Interbody Sales Development effort and International Sales and Marketing的集团经理。Valentine先生目前作为董事，供职于California Healthcare Institute。他在西密歇根大学获得工商管理学士学位和生物医药科学学位。
Keith C. Valentine has served as a member of our board of directors since August 2015. Since June 2015 Mr. Valentine has also served as President, Chief Executive Officer and a member of the board of directors of SeaSpine Holdings Corporation. From January 2007 to January 2015 he served as President and Chief Operating Officer of NuVasive, Inc., a medical device company. From December 2004 to January 2007 he served as President of NuVasive. From January 2001 to December 2004 he held various senior executive roles in marketing, development and operations at NuVasive. Previously, Mr. Valentine served as Vice President of Marketing at ORATEC Interventions, Inc., a medical device company acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic including Vice President of Marketing for the Thoracolumbar Division and Group Director for the BMP Biologics program, Interbody Sales Development, and International Sales and Marketing. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University. - Keith C. Valentine从2007年一月份开始担任我们的主席和首席运营官。在2004年12月到2007年1月期间，他是我们的主席，在2002年1月到2004年12月期间，他是我们的执行副主席。在那之前，他是我们的营销发展高级副主席。他在整形行业有超过20年的经验，曾在ORATEC Interventions, Inc.担任营销副主席，这是一家医疗器械公司，后来被Smith & Nephew plc收购，在Medtronic Sofamor Danek工作的8年时间里，他辗转很多岗位，包括Rods Division市场营销副主席，BMP Biologics program, the Interbody Sales Development effort and International Sales and Marketing的集团经理。Valentine先生目前作为董事，供职于California Healthcare Institute。他在西密歇根大学获得工商管理学士学位和生物医药科学学位。
- Keith C. Valentine has served as a member of our board of directors since August 2015. Since June 2015 Mr. Valentine has also served as President, Chief Executive Officer and a member of the board of directors of SeaSpine Holdings Corporation. From January 2007 to January 2015 he served as President and Chief Operating Officer of NuVasive, Inc., a medical device company. From December 2004 to January 2007 he served as President of NuVasive. From January 2001 to December 2004 he held various senior executive roles in marketing, development and operations at NuVasive. Previously, Mr. Valentine served as Vice President of Marketing at ORATEC Interventions, Inc., a medical device company acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic including Vice President of Marketing for the Thoracolumbar Division and Group Director for the BMP Biologics program, Interbody Sales Development, and International Sales and Marketing. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University.
- John G. Freund
-
John G. Freund，他是医学博士，曾担任我们的董事会成员（2012年10月以来）。他于1997年共同创立Skyline Ventures ，并一直担任合伙人。他曾担任 Chancellor Capital Management私人股本集团（资本管理公司，一个私人资本投资公司）的常务董事。1995年，他共同创立Intuitive Surgical（一个医疗设备公司），直到2000年任职董事会。从1988年到1994年，他担任Acuson公司（超声波设备制造商，现在西门子的一部分）不同职位，最近担任执行副总裁。加入Acuson之前，他是摩根士丹利（Morgan Stanley）的普通合伙人（从1987年到1988年）。从1982年到1988年，他任职摩根士丹利（Morgan Stanley）& Co .）（一家投资银行公司），在那里他于1983年在公司财务部门共同创立医疗集团。他曾任职Concert Pharmaceuticals（一个公开上市的生物制药公司）（自2013年以来），以及，XenoPort （上市生物制药公司）（自1999年以来）。他也服务于三个美国注册投资基金的董事会，如Map Pharmaceuticals（生物制药公司），Hansen Medical（医疗设备公司）和Mako Surgical Corp（医疗设备公司）。他是哈佛商学院（Harvard Business School）的医疗计划顾问委员会成员，并且是哈佛医学院的治疗咨询委员会的成员。他获得哈佛大学的历史学士学位，哈佛医学院医学博士学位，以及哈佛商学院的工商管理硕士学位。
John G. Freund has served as a member of our Board since February 2014. Dr. Freund founded Skyline Ventures “Skyline”, a venture capital firm, in 1997 and has served as Managing Director at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, LLC. In 1995 Dr. Freund co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994 Dr. Freund served in various positions at Acuson Corporation (“Acuson”), most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a General Partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988 Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) (2012 to present) and Proteon Therapeutics, Inc. (NASDAQ: PRTO) (2014 to present), as well as on the boards of two privately held companies, Sutro Biopharma, Inc. (2014 to present) and SI-Bone, Inc. (2013 to present). Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by The Capital Group Companies. He previously served on the board of directors of several publicly traded companies, including XenoPort, Inc. (NASDAQ: XNPT) (1999 to 2016), where he was Chairman, Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (2014 to 2015), MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (2004 to 2011), and MAKO Surgical Corp. (NASDAQ: MAKO) (2008 to 2013). Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund graduated from Harvard College with a B.A. in History in 1975 received an M.D. from Harvard Medical School in 1980 and an M.B.A. from Harvard Business School in 1982. - John G. Freund，他是医学博士，曾担任我们的董事会成员（2012年10月以来）。他于1997年共同创立Skyline Ventures ，并一直担任合伙人。他曾担任 Chancellor Capital Management私人股本集团（资本管理公司，一个私人资本投资公司）的常务董事。1995年，他共同创立Intuitive Surgical（一个医疗设备公司），直到2000年任职董事会。从1988年到1994年，他担任Acuson公司（超声波设备制造商，现在西门子的一部分）不同职位，最近担任执行副总裁。加入Acuson之前，他是摩根士丹利（Morgan Stanley）的普通合伙人（从1987年到1988年）。从1982年到1988年，他任职摩根士丹利（Morgan Stanley）& Co .）（一家投资银行公司），在那里他于1983年在公司财务部门共同创立医疗集团。他曾任职Concert Pharmaceuticals（一个公开上市的生物制药公司）（自2013年以来），以及，XenoPort （上市生物制药公司）（自1999年以来）。他也服务于三个美国注册投资基金的董事会，如Map Pharmaceuticals（生物制药公司），Hansen Medical（医疗设备公司）和Mako Surgical Corp（医疗设备公司）。他是哈佛商学院（Harvard Business School）的医疗计划顾问委员会成员，并且是哈佛医学院的治疗咨询委员会的成员。他获得哈佛大学的历史学士学位，哈佛医学院医学博士学位，以及哈佛商学院的工商管理硕士学位。
- John G. Freund has served as a member of our Board since February 2014. Dr. Freund founded Skyline Ventures “Skyline”, a venture capital firm, in 1997 and has served as Managing Director at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, LLC. In 1995 Dr. Freund co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994 Dr. Freund served in various positions at Acuson Corporation (“Acuson”), most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a General Partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988 Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) (2012 to present) and Proteon Therapeutics, Inc. (NASDAQ: PRTO) (2014 to present), as well as on the boards of two privately held companies, Sutro Biopharma, Inc. (2014 to present) and SI-Bone, Inc. (2013 to present). Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by The Capital Group Companies. He previously served on the board of directors of several publicly traded companies, including XenoPort, Inc. (NASDAQ: XNPT) (1999 to 2016), where he was Chairman, Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (2014 to 2015), MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (2004 to 2011), and MAKO Surgical Corp. (NASDAQ: MAKO) (2008 to 2013). Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund graduated from Harvard College with a B.A. in History in 1975 received an M.D. from Harvard Medical School in 1980 and an M.B.A. from Harvard Business School in 1982.
- Timothy E. Davis, Jr.
-
Timothy E. Davis, Jr.自2012年11月起担任我们OrthoRecon部门的总裁。Davis先生之前自2010年1月至2012年11月担任我们公司的企业发展部的高级副总裁，自2011年5月至2012年11月担任我们公司研究和发展部主管，于2006年至2009年12月担任我们公司业务发展部副总裁。他于2004年至2006年还是MB Venture Partners有限公司的合伙人，这是一家专业从事肌肉骨骼疾病的医学和生命科学技术风险投资公司。Davis先生自1997年至2004年是Vector Fund Management的副总裁，这是一家医疗保健和生命科学风险投资公司。他自1995年至1997年是双子座咨询集团（Gemini Consulting Group）的高级顾问，这是一家医疗咨询公司。他自1992年至1994年是Parke-Davis Company的销售专员，该公司是一家一家制药公司。
Timothy E. Davis, Jr. has served as a member of our board of directors since our inception in April 2008. Mr. Davis has served as President and Chief Executive Officer of Active Implants, LLC, a company that provides orthopedic implant solutions, since February 2017. From January 2014 through September 2015 Mr. Davis served as Chief Executive Officer of MicroPort Orthopedics, Inc., a multinational producer of orthopedic products, following the purchase of Wright Medical Group’s OrthoRecon Business in January 2014. From December 2006 to January 2014 Mr. Davis served in a number of executive positions for Wright Medical Technology, Inc., a subsidiary of Wright Medical Group, Inc., including President of the OrthoRecon business. From 2004 to 2006 Mr. Davis was a Partner with MB Venture Partners, LLC, a medical technology and life sciences venture capital firm. From 1997 to 2004 Mr. Davis held various positions, ultimately serving as Vice President, with Vector Fund Management, a healthcare and life sciences focused venture capital fund. Early in his career, Mr. Davis worked in the healthcare management consulting and pharmaceutical industries. Mr. Davis received a B.E. degree in Biomedical Engineering from Vanderbilt University and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University. - Timothy E. Davis, Jr.自2012年11月起担任我们OrthoRecon部门的总裁。Davis先生之前自2010年1月至2012年11月担任我们公司的企业发展部的高级副总裁，自2011年5月至2012年11月担任我们公司研究和发展部主管，于2006年至2009年12月担任我们公司业务发展部副总裁。他于2004年至2006年还是MB Venture Partners有限公司的合伙人，这是一家专业从事肌肉骨骼疾病的医学和生命科学技术风险投资公司。Davis先生自1997年至2004年是Vector Fund Management的副总裁，这是一家医疗保健和生命科学风险投资公司。他自1995年至1997年是双子座咨询集团（Gemini Consulting Group）的高级顾问，这是一家医疗咨询公司。他自1992年至1994年是Parke-Davis Company的销售专员，该公司是一家一家制药公司。
- Timothy E. Davis, Jr. has served as a member of our board of directors since our inception in April 2008. Mr. Davis has served as President and Chief Executive Officer of Active Implants, LLC, a company that provides orthopedic implant solutions, since February 2017. From January 2014 through September 2015 Mr. Davis served as Chief Executive Officer of MicroPort Orthopedics, Inc., a multinational producer of orthopedic products, following the purchase of Wright Medical Group’s OrthoRecon Business in January 2014. From December 2006 to January 2014 Mr. Davis served in a number of executive positions for Wright Medical Technology, Inc., a subsidiary of Wright Medical Group, Inc., including President of the OrthoRecon business. From 2004 to 2006 Mr. Davis was a Partner with MB Venture Partners, LLC, a medical technology and life sciences venture capital firm. From 1997 to 2004 Mr. Davis held various positions, ultimately serving as Vice President, with Vector Fund Management, a healthcare and life sciences focused venture capital fund. Early in his career, Mr. Davis worked in the healthcare management consulting and pharmaceutical industries. Mr. Davis received a B.E. degree in Biomedical Engineering from Vanderbilt University and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.
高管简历
中英对照 | 中文 | 英文- Jeffrey W. Dunn
自2008年4月成立以来，JeffreyW.Dunn一直担任我们的总裁兼首席执行官，并担任董事会主席。加入我们之前，Dunn从2006年12月到2008年4月担任Inbone Technologies，Inc.（一家踝关节置换和小骨融合医疗设备公司）首席执行官，直到2008年4月出售给Wright Medical Technology，Inc.。Dunn从2000年8月到2006年6月担任Active Decisions，Inc.（一家软件即服务业务）首席执行官，直到该公司出售给Knova Software，Inc.。Dunn从1999年12月到2000年6月担任Velogic，Inc.（一家互联网性能测试软件公司）首席执行官，直到该公司出售给Keynote Systems Inc.。Dunn从1999年6月到1999年12月担任EnterpriseLink Inc.（企业互联网使能软件供应商）首席执行官，直到该公司出售给Merant，Inc.。Dunn从1994年11月到1998年6月担任AccelGraphics Inc.（一家3D图形系统供应商）首席执行官，直到该公司出售给Evans and Sutherland Computer Corporation。在他的职业生涯中，邓恩先生还在埃文斯公司、萨瑟兰公司、Cygnet Systems公司、Avnet，Inc.公司和施乐公司担任过行政职务。Dunn先生在高露洁大学（Colgate University）获得文学学士学位，在巴布森学院（Babson College）获得工商管理硕士学位。
Jeffrey W. Dunn has served as our President and Chief Executive Officer and as the Chairman of our board of directors since our inception in April 2008. Prior to joining us, Mr. Dunn served as Chief Executive Officer of INBONE Technologies, Inc., an ankle replacement and small bone fusion medical device company, from December 2006 to April 2008 until its sale to Wright Medical Technology, Inc. in April 2008. From August 2000 to June 2006 Mr. Dunn was the Chief Executive Officer of Active Decisions, Inc., a software as a service business, until its sale to Knova Software, Inc. From December 1999 to June 2000 Mr. Dunn was the Chief Executive Officer of Velogic, Inc., an internet performance testing software company, until its sale to Keynote Systems Inc. From June 1999 to December 1999 Mr. Dunn was the Chief Executive Officer of EnterpriseLink Inc., a provider of enterprise Internet enablement software, until its sale to Merant, Inc. From November 1994 to June 1998 Mr. Dunn was Chief Executive Officer of AccelGraphics Inc., a 3D graphics system supplier, until its sale to Evans and Sutherland Computer Corporation. As well, during his career, Mr. Dunn held executive positions with Evans and Sutherland, Cygnet Systems, Inc., Avnet, Inc. and Xerox Corporation. Mr. Dunn received a B.A. from Colgate University and an M.B.A. from Babson College.- 自2008年4月成立以来，JeffreyW.Dunn一直担任我们的总裁兼首席执行官，并担任董事会主席。加入我们之前，Dunn从2006年12月到2008年4月担任Inbone Technologies，Inc.（一家踝关节置换和小骨融合医疗设备公司）首席执行官，直到2008年4月出售给Wright Medical Technology，Inc.。Dunn从2000年8月到2006年6月担任Active Decisions，Inc.（一家软件即服务业务）首席执行官，直到该公司出售给Knova Software，Inc.。Dunn从1999年12月到2000年6月担任Velogic，Inc.（一家互联网性能测试软件公司）首席执行官，直到该公司出售给Keynote Systems Inc.。Dunn从1999年6月到1999年12月担任EnterpriseLink Inc.（企业互联网使能软件供应商）首席执行官，直到该公司出售给Merant，Inc.。Dunn从1994年11月到1998年6月担任AccelGraphics Inc.（一家3D图形系统供应商）首席执行官，直到该公司出售给Evans and Sutherland Computer Corporation。在他的职业生涯中，邓恩先生还在埃文斯公司、萨瑟兰公司、Cygnet Systems公司、Avnet，Inc.公司和施乐公司担任过行政职务。Dunn先生在高露洁大学（Colgate University）获得文学学士学位，在巴布森学院（Babson College）获得工商管理硕士学位。
- Jeffrey W. Dunn has served as our President and Chief Executive Officer and as the Chairman of our board of directors since our inception in April 2008. Prior to joining us, Mr. Dunn served as Chief Executive Officer of INBONE Technologies, Inc., an ankle replacement and small bone fusion medical device company, from December 2006 to April 2008 until its sale to Wright Medical Technology, Inc. in April 2008. From August 2000 to June 2006 Mr. Dunn was the Chief Executive Officer of Active Decisions, Inc., a software as a service business, until its sale to Knova Software, Inc. From December 1999 to June 2000 Mr. Dunn was the Chief Executive Officer of Velogic, Inc., an internet performance testing software company, until its sale to Keynote Systems Inc. From June 1999 to December 1999 Mr. Dunn was the Chief Executive Officer of EnterpriseLink Inc., a provider of enterprise Internet enablement software, until its sale to Merant, Inc. From November 1994 to June 1998 Mr. Dunn was Chief Executive Officer of AccelGraphics Inc., a 3D graphics system supplier, until its sale to Evans and Sutherland Computer Corporation. As well, during his career, Mr. Dunn held executive positions with Evans and Sutherland, Cygnet Systems, Inc., Avnet, Inc. and Xerox Corporation. Mr. Dunn received a B.A. from Colgate University and an M.B.A. from Babson College.
- Laura A. Francis
LauraA.Francis自2015年5月起担任我们的首席财务官。在加入我们之前，Francis女士于2012年12月至2014年9月担任Auxogyn，Inc.（一家女性健康公司）的首席财务官。2004年9月至2012年12月，Francis女士担任生命科学试剂公司Promega Corporation的财务Vice President、首席财务官和财务主管。2002年3月至2004年9月，Francis女士担任Bruker Biosciences Corporation（一家公共生命科学仪器公司）的首席财务官。2001年5月至2002年3月，Francis女士担任Nutra-Park Inc.（一家农业生物技术公司）的首席运营官和首席财务官。Francis从1999年4月到2001年5月担任Hypercosm，Inc.（一家软件公司）首席财务官。Francis从1995年10月到1999年4月担任McKinsey&Company（一家咨询公司）业务经理。在她的职业生涯早期，Francis女士是会计师事务所Coopers&Lybrand的审计经理。Francis女士在威斯康星大学（University of Wisconsin）获得工商管理学士学位，在斯坦福大学（Stanford University）获得工商管理硕士学位。她是加州不活跃的注册会计师。
Laura A. Francis has served as our Chief Financial Officer since May 2015. Prior to joining us, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women’s health company, from December 2012 to September 2014. From September 2004 to December 2012 Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004 Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002 Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001 Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999 Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant inactive in the State of California.- LauraA.Francis自2015年5月起担任我们的首席财务官。在加入我们之前，Francis女士于2012年12月至2014年9月担任Auxogyn，Inc.（一家女性健康公司）的首席财务官。2004年9月至2012年12月，Francis女士担任生命科学试剂公司Promega Corporation的财务Vice President、首席财务官和财务主管。2002年3月至2004年9月，Francis女士担任Bruker Biosciences Corporation（一家公共生命科学仪器公司）的首席财务官。2001年5月至2002年3月，Francis女士担任Nutra-Park Inc.（一家农业生物技术公司）的首席运营官和首席财务官。Francis从1999年4月到2001年5月担任Hypercosm，Inc.（一家软件公司）首席财务官。Francis从1995年10月到1999年4月担任McKinsey&Company（一家咨询公司）业务经理。在她的职业生涯早期，Francis女士是会计师事务所Coopers&Lybrand的审计经理。Francis女士在威斯康星大学（University of Wisconsin）获得工商管理学士学位，在斯坦福大学（Stanford University）获得工商管理硕士学位。她是加州不活跃的注册会计师。
- Laura A. Francis has served as our Chief Financial Officer since May 2015. Prior to joining us, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women’s health company, from December 2012 to September 2014. From September 2004 to December 2012 Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004 Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002 Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001 Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999 Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant inactive in the State of California.
- Michael A. Pisetsky
MichaelA.Pisetsky自2016年8月起担任我们的总法律顾问兼首席合规官。Pisetsky先生于2015年3月加入我们，担任我们的法律总监。2011年8月至2015年3月，Pisetsky先生私人执业，担任New Wave Surgical Corp.和Mark Properties，Inc.（东南部大型购物中心运营商）的总法律顾问，以及医疗技术和梦百合服务领域的其他一些公司。2008年8月至2011年7月，Pisetsky先生是Palo Alto Cooley LLP业务部的助理，代表医疗技术、生物技术、梦百合服务和一般技术客户的投资组合，从成立到公开发行和最终出售。Pisetsky先生在哈佛学院（Harvard College）以优异成绩获得学士学位。Pisetsky先生以优异成绩获得杜克大学法学博士学位和工商管理硕士学位，包括卫生部门管理证书。
Michael A. Pisetsky has served as our General Counsel and Chief Compliance Officer since August 2016. Mr. Pisetsky joined us in March 2015 as our Director of Legal. From August 2011 to March 2015 Mr. Pisetsky practiced law privately, serving as General Counsel to New Wave Surgical Corp. and Mark Properties, Inc. a large operator of shopping centers in the Southeast, among a number of other companies in the medical technology and healthcare services space. From August 2008 to July 2011 Mr. Pisetsky was an Associate in the Business Department at Cooley LLP in Palo Alto, representing a portfolio of medical technology, biotech, healthcare services and general technology clients, from inception to public offering and eventual sale. Mr. Pisetsky received his B.A. with Honors from Harvard College. Mr. Pisetsky received his J.D. magna cum laude and M.B.A., including a certificate in Health Sector Management, concurrently from Duke University.- MichaelA.Pisetsky自2016年8月起担任我们的总法律顾问兼首席合规官。Pisetsky先生于2015年3月加入我们，担任我们的法律总监。2011年8月至2015年3月，Pisetsky先生私人执业，担任New Wave Surgical Corp.和Mark Properties，Inc.（东南部大型购物中心运营商）的总法律顾问，以及医疗技术和梦百合服务领域的其他一些公司。2008年8月至2011年7月，Pisetsky先生是Palo Alto Cooley LLP业务部的助理，代表医疗技术、生物技术、梦百合服务和一般技术客户的投资组合，从成立到公开发行和最终出售。Pisetsky先生在哈佛学院（Harvard College）以优异成绩获得学士学位。Pisetsky先生以优异成绩获得杜克大学法学博士学位和工商管理硕士学位，包括卫生部门管理证书。
- Michael A. Pisetsky has served as our General Counsel and Chief Compliance Officer since August 2016. Mr. Pisetsky joined us in March 2015 as our Director of Legal. From August 2011 to March 2015 Mr. Pisetsky practiced law privately, serving as General Counsel to New Wave Surgical Corp. and Mark Properties, Inc. a large operator of shopping centers in the Southeast, among a number of other companies in the medical technology and healthcare services space. From August 2008 to July 2011 Mr. Pisetsky was an Associate in the Business Department at Cooley LLP in Palo Alto, representing a portfolio of medical technology, biotech, healthcare services and general technology clients, from inception to public offering and eventual sale. Mr. Pisetsky received his B.A. with Honors from Harvard College. Mr. Pisetsky received his J.D. magna cum laude and M.B.A., including a certificate in Health Sector Management, concurrently from Duke University.
- W. Carlton Reckling
W.Carlton Reckling自2012年4月起担任医疗事务Vice President，自2017年2月起担任首席医疗官。从1994年7月到2012年4月，Reckling博士是科罗拉多州洛夫兰脊柱中心的脊柱外科医生，怀俄明州夏延市落基山脉骨科专家，怀俄明州夏延市脊柱和骨科手术中心，怀俄明州夏延市骨科手术协会，以及明尼苏达州圣保罗的Ramsey医院和诊所。Reckling博士在西北大学（Northwestern University）获得化学工程学士学位，在克雷顿大学（Creighton University）获得医学博士学位，在怀俄明大学（University of Wyoming）获得工商管理硕士学位。他在明尼苏达大学（University of Minnesota）完成了整形外科的实习和住院医师资格。在明尼苏达州项目期间，他在双城脊柱侧弯中心度过了一段时间。他在英国诺丁汉的Queen&8217；s University Medical Centre完成脊柱外科研究金。Reckling博士还在明尼苏达州明尼阿波利斯的明尼苏达大学（University of Minnesota）医院和诊所接受了普通外科的额外培训。Reckling博士是一名委员会认证的骨科脊柱外科医生。
W. Carlton Reckling has served as our Vice President, Medical Affairs since April 2012 and our Chief Medical Officer since February 2017. From July 1994 to April 2012 Dr. Reckling was a spine surgeon at the Spine Center in Loveland, Colorado, Rocky Mountain Orthopedic Specialists in Cheyenne, Wyoming, the Center for Spine & Orthopedic Surgery in Cheyenne, Wyoming, Associates in Orthopedic Surgery in Cheyenne, Wyoming, and Ramsey Hospital and Clinics in St. Paul, Minnesota. Dr. Reckling received a B.S. in Chemical Engineering from Northwestern University, an M.D. from Creighton University, and an M.B.A. from the University of Wyoming. He completed his internship and his residency in orthopedic surgery at the University of Minnesota. While in the Minnesota program, he spent time at the Twin Cities Scoliosis Center. He completed his fellowship in spine surgery at Queen’s University Medical Centre in Nottingham, England. Dr. Reckling also underwent additional training in general surgery at the University of Minnesota Hospitals and Clinics in Minneapolis, Minnesota. Dr. Reckling is a board-certified orthopedic spine surgeon.- W.Carlton Reckling自2012年4月起担任医疗事务Vice President，自2017年2月起担任首席医疗官。从1994年7月到2012年4月，Reckling博士是科罗拉多州洛夫兰脊柱中心的脊柱外科医生，怀俄明州夏延市落基山脉骨科专家，怀俄明州夏延市脊柱和骨科手术中心，怀俄明州夏延市骨科手术协会，以及明尼苏达州圣保罗的Ramsey医院和诊所。Reckling博士在西北大学（Northwestern University）获得化学工程学士学位，在克雷顿大学（Creighton University）获得医学博士学位，在怀俄明大学（University of Wyoming）获得工商管理硕士学位。他在明尼苏达大学（University of Minnesota）完成了整形外科的实习和住院医师资格。在明尼苏达州项目期间，他在双城脊柱侧弯中心度过了一段时间。他在英国诺丁汉的Queen&8217；s University Medical Centre完成脊柱外科研究金。Reckling博士还在明尼苏达州明尼阿波利斯的明尼苏达大学（University of Minnesota）医院和诊所接受了普通外科的额外培训。Reckling博士是一名委员会认证的骨科脊柱外科医生。
- W. Carlton Reckling has served as our Vice President, Medical Affairs since April 2012 and our Chief Medical Officer since February 2017. From July 1994 to April 2012 Dr. Reckling was a spine surgeon at the Spine Center in Loveland, Colorado, Rocky Mountain Orthopedic Specialists in Cheyenne, Wyoming, the Center for Spine & Orthopedic Surgery in Cheyenne, Wyoming, Associates in Orthopedic Surgery in Cheyenne, Wyoming, and Ramsey Hospital and Clinics in St. Paul, Minnesota. Dr. Reckling received a B.S. in Chemical Engineering from Northwestern University, an M.D. from Creighton University, and an M.B.A. from the University of Wyoming. He completed his internship and his residency in orthopedic surgery at the University of Minnesota. While in the Minnesota program, he spent time at the Twin Cities Scoliosis Center. He completed his fellowship in spine surgery at Queen’s University Medical Centre in Nottingham, England. Dr. Reckling also underwent additional training in general surgery at the University of Minnesota Hospitals and Clinics in Minneapolis, Minnesota. Dr. Reckling is a board-certified orthopedic spine surgeon.
- Anthony J. Recupero
AnthonyJ.Recupero自2016年7月起担任我们的首席商务官。在加入我们之前，Recupero先生曾担任Catalyst Performance Advisors，LLC的总裁，在那里他曾于2013年6月至2016年7月为领先的医疗器械公司提供商业策略建议。Recupero先生于2008年7月加入Baxano，Inc.，该公司是一家医疗器械公司，拥有微创产品，以治疗影响腰椎区域的脊柱退行性疾病，最初担任销售与市场营销的Vice President，2009年2月晋升为总裁兼首席执行官，直到2013年6月被Trans1收购。从2005年1月到2008年7月，他曾担任Recupero Consulting Group公司的总裁，在那里他曾建议领先的医疗设备公司的商业战略。Recupero从1999年10月到2004年12月担任Kyphon销售Vice President。职业生涯早期，Recupero先生在United States Surgical Corporation和Sulzer Spine-Tech，Inc.担任高级销售管理职位。Recupero先生在纽约州立大学奥尔巴尼分校获得通信学士学位。
Anthony J. Recupero has served as our Chief Commercial Officer since July 2016. Prior to joining us, Mr. Recupero was the President of Catalyst Performance Advisors, LLC, where he advised leading medical device companies on commercial strategy from June 2013 to July 2016. In July 2008 Mr. Recupero joined Baxano, Inc., a medical device company with minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, initially as Vice President of Sales and Marketing and was promoted in February 2009 to President and Chief Executive Officer until its acquisition by TranS1 in June 2013. From January 2005 to July 2008 Mr. Recupero was President of Recupero Consulting Group, LLC, where he advised leading medical device companies on commercial strategy. From October 1999 to December 2004 Mr. Recupero was the Vice President of Sales for Kyphon. Early in his career, Mr. Recupero progressed to senior sales management roles at United States Surgical Corporation and Sulzer Spine-Tech, Inc. Mr. Recupero received a B.A. in Communications from State University of New York at Albany.- AnthonyJ.Recupero自2016年7月起担任我们的首席商务官。在加入我们之前，Recupero先生曾担任Catalyst Performance Advisors，LLC的总裁，在那里他曾于2013年6月至2016年7月为领先的医疗器械公司提供商业策略建议。Recupero先生于2008年7月加入Baxano，Inc.，该公司是一家医疗器械公司，拥有微创产品，以治疗影响腰椎区域的脊柱退行性疾病，最初担任销售与市场营销的Vice President，2009年2月晋升为总裁兼首席执行官，直到2013年6月被Trans1收购。从2005年1月到2008年7月，他曾担任Recupero Consulting Group公司的总裁，在那里他曾建议领先的医疗设备公司的商业战略。Recupero从1999年10月到2004年12月担任Kyphon销售Vice President。职业生涯早期，Recupero先生在United States Surgical Corporation和Sulzer Spine-Tech，Inc.担任高级销售管理职位。Recupero先生在纽约州立大学奥尔巴尼分校获得通信学士学位。
- Anthony J. Recupero has served as our Chief Commercial Officer since July 2016. Prior to joining us, Mr. Recupero was the President of Catalyst Performance Advisors, LLC, where he advised leading medical device companies on commercial strategy from June 2013 to July 2016. In July 2008 Mr. Recupero joined Baxano, Inc., a medical device company with minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, initially as Vice President of Sales and Marketing and was promoted in February 2009 to President and Chief Executive Officer until its acquisition by TranS1 in June 2013. From January 2005 to July 2008 Mr. Recupero was President of Recupero Consulting Group, LLC, where he advised leading medical device companies on commercial strategy. From October 1999 to December 2004 Mr. Recupero was the Vice President of Sales for Kyphon. Early in his career, Mr. Recupero progressed to senior sales management roles at United States Surgical Corporation and Sulzer Spine-Tech, Inc. Mr. Recupero received a B.A. in Communications from State University of New York at Albany.
- Scott A. Yerby
ScottA.Yerby自2011年1月以来一直担任我们的首席技术官。在加入我们之前，2009年6月至2011年1月，Yerby博士担任医疗用品公司ProMed，Inc.的Vice President、研究与开发。从2007年5月到2009年6月，Yerby博士担任几个非营利组织的董事。Yerby从2000年6月到2007年5月担任St.Francis Medical Technologies，Inc.（一家脊柱制造公司）研究与开发Vice President，直到该公司被Kyphon，Inc.收购。Yerby从1997年6月到2000年6月担任the Palo Alto VA Hospital实验生物力学主管。在职业生涯早期，Yerby博士在斯坦福大学（Stanford University）的生物力学工程系机械工程系和骨科手术系功能修复系担任咨询助理教授。Yerby博士在加州大学戴维斯分校（University of California，Davis）获得机械工程B.S.和M.S.学位以及生物医学工程博士学位。
Scott A. Yerby has served as our Chief Technology Officer since January 2011. Prior to joining us, Dr. Yerby served as Vice President, Research and Development for ProMed, Inc., a medical supply company, from June 2009 to January 2011. From May 2007 to June 2009 Dr. Yerby sat on the board of several non-profit organizations. From June 2000 to May 2007 Dr. Yerby served as Vice President of Research and Development for St. Francis Medical Technologies, Inc., a spinal manufacturing company, until its acquisition by Kyphon, Inc. From June 1997 to June 2000 Dr. Yerby served as Director of Experimental Biomechanics at the Palo Alto VA Hospital. Early in his career, Dr. Yerby held appointments as Consulting Assistant Professor at Stanford University in the Department of Mechanical Engineering, Division of Biomechanical Engineering, and the Department of Functional Restoration, Division of Orthopedic Surgery. Dr. Yerby received B.S. and M.S. degrees in Mechanical Engineering and a Ph.D. in Biomedical Engineering, all from the University of California, Davis.- ScottA.Yerby自2011年1月以来一直担任我们的首席技术官。在加入我们之前，2009年6月至2011年1月，Yerby博士担任医疗用品公司ProMed，Inc.的Vice President、研究与开发。从2007年5月到2009年6月，Yerby博士担任几个非营利组织的董事。Yerby从2000年6月到2007年5月担任St.Francis Medical Technologies，Inc.（一家脊柱制造公司）研究与开发Vice President，直到该公司被Kyphon，Inc.收购。Yerby从1997年6月到2000年6月担任the Palo Alto VA Hospital实验生物力学主管。在职业生涯早期，Yerby博士在斯坦福大学（Stanford University）的生物力学工程系机械工程系和骨科手术系功能修复系担任咨询助理教授。Yerby博士在加州大学戴维斯分校（University of California，Davis）获得机械工程B.S.和M.S.学位以及生物医学工程博士学位。
- Scott A. Yerby has served as our Chief Technology Officer since January 2011. Prior to joining us, Dr. Yerby served as Vice President, Research and Development for ProMed, Inc., a medical supply company, from June 2009 to January 2011. From May 2007 to June 2009 Dr. Yerby sat on the board of several non-profit organizations. From June 2000 to May 2007 Dr. Yerby served as Vice President of Research and Development for St. Francis Medical Technologies, Inc., a spinal manufacturing company, until its acquisition by Kyphon, Inc. From June 1997 to June 2000 Dr. Yerby served as Director of Experimental Biomechanics at the Palo Alto VA Hospital. Early in his career, Dr. Yerby held appointments as Consulting Assistant Professor at Stanford University in the Department of Mechanical Engineering, Division of Biomechanical Engineering, and the Department of Functional Restoration, Division of Orthopedic Surgery. Dr. Yerby received B.S. and M.S. degrees in Mechanical Engineering and a Ph.D. in Biomedical Engineering, all from the University of California, Davis.